Phase 2 Crohn's Disease and Colitis Trial, Recruiting NCT04970446 Sponsor: St Vincent's Hospital Melbourne Condition: Crohn's Disease and Colitis
Back to Crohns Disease And Colitis

Phase 2 Crohn's Disease and Colitis Trial, Recruiting

NCT04970446
Recruiting Phase 2 🇦🇺 Australian site

voxsanity.com.au · Eligibility summary from public government registries · 18 August 2026 · not medical advice

Who may and may not be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who may be able to join

  • You have been diagnosed with active Crohn's disease that has been confirmed by a camera test (endoscopy) showing active inflammation within the last 6 months — or, if your disease is in a part of the small bowel that can't be reached by endoscopy, an ultrasound scan showing inflammation is acceptable instead.
  • Your Crohn's disease activity score (a measurement of your symptoms called CDAI) falls between 220 and 450.
  • You have at least one of the following signs of inflammation: a raised CRP blood test result (5mg/L or above), a raised stool test result called faecal calprotectin (100μg/g or above), or signs of inflammation seen on an ultrasound or MRI scan.
  • You are willing and able to visit the study sites regularly for camera (endoscopy) procedures.

Who may not be able to join

Each point below is a reason the trial team may not be able to accept someone. It is not a list of requirements to meet.

  • You have active disease around the anal area or have tunnels/passages (fistulas) caused by Crohn's disease.
  • You are pregnant or planning to become pregnant within the next 12 months.
  • You have a gut or bowel condition other than Crohn's disease causing inflammation.
  • You have a narrowing (stricture) in your bowel that is causing symptoms and is likely to need surgery.
  • You have a stoma (a surgically created opening on your abdomen for waste).
  • You have had a surgical pouch created as part of bowel surgery (ileoanal pouch).
  • Your white blood cell count is too low (below 3.0 x 10⁹/L) (confirm with trial site).
  • Your albumin (a protein measured in your blood) level is below 20g/L, which may indicate poor nutrition (confirm with trial site).
  • You have a weakened immune system for reasons other than medications taken for your Crohn's disease — for example, HIV or a condition called Common Variable Immune Deficiency.
  • You have a history of severe allergic reactions (anaphylaxis) to food.
  • Your dose of certain Crohn's medications — including thiopurines, methotrexate, biologic treatments, small molecule inhibitors, or aminosalicylates — has been changed too recently before joining the study (the exact timeframes vary by medication, so confirm with the trial site).
  • You have used prebiotics, probiotics, antibiotics, or over-the-counter supplements in the two weeks before joining the study.
  • You have used rectal (back passage) treatments for Crohn's disease in the two weeks before joining the study.
  • You are taking a steroid dose higher than the permitted level (prednisolone above 20mg or budesonide above 6mg).
  • You are unwilling or unable to gradually reduce and stop corticosteroid (steroid) medications within 8 weeks of the start of the treatment being studied.
  • You currently have an active infection in your gut or digestive system.
  • You drink alcohol at a dependent level.
  • You have a liver condition called primary sclerosing cholangitis.
  • Your gastroenterologist (gut specialist) believes there is any reason that taking part could put your health at risk (confirm with trial site).
  • The medical team feels you are not able to safely take part in the treatment being studied (confirm with trial site).

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 29 July 2026

Contact this trial

Principal Investigator: Michael A Kamm, MD, St Vincents Hospital

Phone: 0392311352

Australian sites

St Vincents Hospital, Melbourne, Victoria

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
St Vincent's Hospital Melbourne
Registry
ClinicalTrials.gov
Start date
1 May 2022
Est. completion
1 April 2025

This date has passed while the registry still lists the trial as open to participants. Sponsors often update a trial's status without revising its projected end date, so it may well still be recruiting — but the record is out of date in at least one respect. Check with the study contact before relying on either.

Where this trial is recruiting

🇦🇺 Australia

1 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Clinical response

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 29 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov